JeongMin Sim
Overview
Explore the profile of JeongMin Sim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
56
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Park J, Kim D, Sim J, Kim Y, Cho K, Moon J, et al.
Brain Tumor Res Treat
. 2024 Nov;
12(4):237-244.
PMID: 39542520
Background: Among gliomas, the most common primary malignant brain tumor, incidental gliomas account for 2.5%-5% of cases. The controversy over whether to pursue immediate treatment or adopt a wait-and-see approach...
2.
Park J, Kim Y, Lee M, Kim D, Sim J, Cho K, et al.
J Neurooncol
. 2024 Jun;
169(3):543-553.
PMID: 38907949
Purpose: LLT-1 is a well-known ligand for the natural killer (NK) cell inhibitory receptor NKRP1A. Here, we examined NLRC4 inflammasome components and LLT-1 expression in glioblastoma (GBM) tissues to elucidate...
3.
Sim J, Park J, Moon J, Lim J
Cell Commun Signal
. 2023 Sep;
21(1):239.
PMID: 37723542
Gliomas are the most common brain tumors characterized by complicated heterogeneity. The genetic, molecular, and histological pathology of gliomas is characterized by high neuro-inflammation. The inflammatory microenvironment in the central...
4.
Kim Y, Choi W, Sim J, Ahn J, Park J, Kim D, et al.
Brain Tumor Res Treat
. 2023 Aug;
11(3):191-203.
PMID: 37550819
Background: Inflammasomes are key in the initiation of inflammatory responses and serve to defend the organism. However, when the immune system is imbalanced, these complexes contribute to tumor progression. The...
5.
Sim J, Ahn J, Park J, Kim Y, Jeong J, Lee J, et al.
Inflamm Res
. 2023 Mar;
72(4):813-827.
PMID: 36899084
Background: The present study was designed to explore the pathological role of non-canonical NLRC4 inflammasome in glioma. Methods: This retrospective study included bioinformatical analysis, including survival, gene ontology, ssGSEA, cox...
6.
Park J, Sim J, Ahn J, Kim Y, Hwang S, Cho K, et al.
J Neurosurg
. 2022 Aug;
138(3):629-638.
PMID: 35986732
Objective: Several limitations are associated with the early diagnosis and treatment of incidental lower-grade glioma (iLGG), and due to its unknown molecular features, its management is categorized as either the...
7.
Kim S, Park Y, Ahn J, Sim J, Park J, Kim Y, et al.
J Clin Med
. 2022 Jun;
11(11).
PMID: 35683607
Traumatic brain injury (TBI) occurs frequently, and acute TBI requiring surgical treatment is closely related to patient survival. Models for predicting the prognosis of patients with TBI do not consider...
8.
Sim J, Park J, Kim S, Hwang S, Sung K, Lee J, et al.
Int J Mol Sci
. 2022 Feb;
23(4).
PMID: 35216164
Tim-3/Gal-9 and the NLRC4 inflammasome contribute to glioma progression. However, the underlying mechanisms involved are unclear. Here, we observed that Tim-3/Gal-9 expression increased with glioma malignancy and found that Tim-3/Gal-9...
9.
Park Y, Park M, Kim J, Ahn J, Sim J, Bang J, et al.
Cancers (Basel)
. 2022 Feb;
14(3).
PMID: 35158782
The alteration of the cellular metabolism is a hallmark of glioma. The high glycolytic phenotype is a critical factor in the pathogenesis of high-grade glioma, including glioblastoma multiforme (GBM). GBM...
10.
Lim J, Park Y, Ahn J, Sim J, Kang S, Hwang S, et al.
PLoS One
. 2021 Mar;
16(3):e0247293.
PMID: 33690665
Glioblastoma multiforme (GBM) is an aggressive malignancy classified by the World Health Organization as a grade IV glioma. Despite the availability of aggressive standard therapies, most patients experience recurrence, for...